159 related articles for article (PubMed ID: 16810611)
1. Effects of anagrelide on megakaryopoiesis and platelet production.
Thiele J; Kvasnicka HM; Schmitt-Graeff A
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):352-61. PubMed ID: 16810611
[TBL] [Abstract][Full Text] [Related]
2. Anagrelide does not exert a myelodysplastic effect on megakaryopoiesis: a comparative immunohistochemical and morphometric study with hydroxyurea.
Thiele J; Kvasnicka HM; Ollig S; Schmitt-Gräff A
Histol Histopathol; 2005 Oct; 20(4):1071-6. PubMed ID: 16136489
[TBL] [Abstract][Full Text] [Related]
3. [Anagrelide-induced changes of megakaryopoiesis during therapy of chronic myeloproliferative disorders with thrombocythemia].
Thiele J; Kvasnicka HM; Schmitt-Gräff A
Pathologe; 2002 Nov; 23(6):426-32. PubMed ID: 12436295
[TBL] [Abstract][Full Text] [Related]
4. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia.
Harrison CN; Campbell PJ; Buck G; Wheatley K; East CL; Bareford D; Wilkins BS; van der Walt JD; Reilly JT; Grigg AP; Revell P; Woodcock BE; Green AR;
N Engl J Med; 2005 Jul; 353(1):33-45. PubMed ID: 16000354
[TBL] [Abstract][Full Text] [Related]
5. Anagrelide: what was new in 2004 and 2005?
Petrides PE
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):399-408. PubMed ID: 16810615
[TBL] [Abstract][Full Text] [Related]
6. When and how to treat essential thrombocythemia.
Barbui T; Finazzi G
N Engl J Med; 2005 Jul; 353(1):85-6. PubMed ID: 16000360
[No Abstract] [Full Text] [Related]
7. Anagrelide platelet-lowering effect is due to inhibition of both megakaryocyte maturation and proplatelet formation: insight into potential mechanisms.
Espasandin YR; Glembotsky AC; Grodzielski M; Lev PR; Goette NP; Molinas FC; Marta RF; Heller PG
J Thromb Haemost; 2015 Apr; 13(4):631-42. PubMed ID: 25604267
[TBL] [Abstract][Full Text] [Related]
8. Anagrelide as a new platelet-lowering agent in essential thrombocythemia: mechanism of actin, efficacy, toxicity, current indications.
Tefferi A; Silverstein MN; Petitt RM; Mesa RA; Solberg LA
Semin Thromb Hemost; 1997; 23(4):379-83. PubMed ID: 9263355
[TBL] [Abstract][Full Text] [Related]
9. Anagrelide-induced bone marrow changes during therapy of chronic myeloproliferative disorders with thrombocytosis. an immunohistochemical and morphometric study of sequential trephine biopsies.
Thiele J; Kvasnicka HM; Fuchs N; Brunnbauer K; Volkwein N; Schmitt-Graeff A
Haematologica; 2003 Oct; 88(10):1130-8. PubMed ID: 14555309
[TBL] [Abstract][Full Text] [Related]
10. Effects of anagrelide on in vivo megakaryocyte proliferation and maturation in essential thrombocythemia.
Tomer A
Blood; 2002 Mar; 99(5):1602-9. PubMed ID: 11861274
[TBL] [Abstract][Full Text] [Related]
11. [Essential thrombocythemia: therapy with anagrelide].
Mazzucconi MG; Ferrari A; Balduini CL
Haematologica; 1991 Jun; 76 Suppl 3():378-81. PubMed ID: 1661268
[No Abstract] [Full Text] [Related]
12. Treatment of Essential Thrombocythemia with Anagrelide Is Associated with an Increased Risk of Worsened Kidney Function.
Kwiatkowski J; Kuliszkiewicz-Janus M; Rymer W; Jaźwiec B; Małecki R
Pharmacology; 2021; 106(5-6):316-322. PubMed ID: 33691325
[TBL] [Abstract][Full Text] [Related]
13. The Use of Anagrelide in Myeloproliferative Neoplasms, with Focus on Essential Thrombocythemia.
Birgegård G
Curr Hematol Malig Rep; 2016 Oct; 11(5):348-55. PubMed ID: 27497846
[TBL] [Abstract][Full Text] [Related]
14. Anagrelide-induced relapse of a hydroxyurea-induced leg ulcer in a patient with primary thrombocythemia.
Ruiz-Argüelles GJ; Ruiz-Delgado GJ; Ruiz-Reyes G; Chernoff SG
Mayo Clin Proc; 1998 Nov; 73(11):1125. PubMed ID: 9818051
[No Abstract] [Full Text] [Related]
15. Essential thrombocythemia: diagnosis and treatment, with special emphasis on the use of anagrelide.
Andersson BS
Hematology; 2002 Jun; 7(3):173-7. PubMed ID: 12243981
[No Abstract] [Full Text] [Related]
16. [Megakaryopoietic cytokine levels in patients with essential thrombocythemia and their relationship with clinical and biochemical features].
Marta RF; Goette NP; Molinas FC
Medicina (B Aires); 2006; 66(6):540-6. PubMed ID: 17240625
[TBL] [Abstract][Full Text] [Related]
17. Decreased survival and increased rate of fibrotic progression in essential thrombocythemia chronicled after the FDA approval date of anagrelide.
Tefferi A; Szuber N; Vallapureddy RR; Begna KH; Patnaik MM; Elliott MA; Christopher Hook C; Wolanskyj AP; Hanson CA; Ketterling RP; Pardanani A; Gangat N
Am J Hematol; 2019 Jan; 94(1):5-9. PubMed ID: 30252953
[TBL] [Abstract][Full Text] [Related]
18. Anagrelide: new drug. Essential thrombocythaemia: further evaluation needed for this last-resort treatment.
Prescrire Int; 2006 Jun; 15(83):83-6. PubMed ID: 16764090
[TBL] [Abstract][Full Text] [Related]
19. Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial.
Gisslinger H; Gotic M; Holowiecki J; Penka M; Thiele J; Kvasnicka HM; Kralovics R; Petrides PE;
Blood; 2013 Mar; 121(10):1720-8. PubMed ID: 23315161
[TBL] [Abstract][Full Text] [Related]
20. Effect of anagrelide on platelet coagulant function in patients with essential thrombocythemia.
Cacciola RR; Di Francesco E; Pezzella F; Tibullo D; Giustolisi R; Cacciola E
Acta Haematol; 2007; 118(4):215-8. PubMed ID: 18057866
[No Abstract] [Full Text] [Related]
[Next] [New Search]
